Advanced Treatments Create New Prospects for Patients and Their Healthcare Providers New FDA-approved medical treatments can be transformative for patients and families, often providing them with more ...

The importance of hypertension of the pulmonary circulation in the natural history of mitral stenosis has been appreciated for many years. Many of the classic signs of this type of cardiac disease ...

If you have pulmonary hypertension, it means you have high blood pressure in your pulmonary arteries, the blood vessels that carry blood from the right side of your heart through your lungs.

Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy ...

"Pulmonary hypertension usually affects people aged 30 to 60. Its early signs and symptoms can mimic those of various other medical conditions, making early detection challenging," explains Dr Garde.

Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...

Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...

The new analysis, they note, further verifies that while the use of either e-cigarettes or traditional “combustible” ...

cholesterol the role of natriuretic peptide signaling and mineralocorticoid receptor antagonism in protecting against adverse remodeling in the pressure-overloaded heart the molecular pathogenesis of ...

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension.